Abstract
Recent studies in metastatic castration-sensitive prostate cancer have highlighted the potential benefits of giving systemic treatment with androgen deprivation earlier. Although such an approach might significantly improve survival, data showing such an effect may not be available for many years after trial initiation, and intermediate end points might facilitate future studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
